A novel sialyl LeX expression score as a potential prognostic tool in colorectal cancer

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Schiffmann, Leif ^a   Schwarz, Fabian ^a   Linnebacher, Michael ^a   Prall, Friedrich ^a   Pahnke, Jens ^a   Krentz, Helga ^a   Vollmar, Brigitte ^a   Klar, Ernst ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Colorectal cancer; Prognosis; Sialyl le x; Tumor staging

Indexed keywords

SIALYL LEWIS X ANTIGEN;

ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT;

AGED; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; OLIGOSACCHARIDES; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861334017     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-95     Document Type: Article

References (22)

1. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. and Robert Koch-Institut, Krebs in Deutschland - Häufigkeiten und Trends 2006, p108. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V, Saarbrücken, 5.
2. Staib L, Link KH, Blatz A, Beger HG. Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients - a monoinstitutional experience. World J Surg 2002, 26:59-66. 10.1007/s00268-001-0182-5, 11898035.
3. Davis NC, Evans EB, Cohen JR, Theile DE, Job DM. Colorectal cancer: a large unselected Australian series. Aust N Z J Surg 1987, 57:153-159. 10.1111/j.1445-2197.1987.tb01326.x, 2441690.
4. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br J Cancer 2009, 100:1704-1719. 10.1038/sj.bjc.6605061, 2695695, 19436303.
5. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. NEJM 2005, 352:476-487. 10.1056/NEJMra040958, 15689586.
6. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y, Irimura T. Increased expression of sialyl Lewis x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993, 53:3632-3637.
7. Nakagoe T, Fukushima K, Hirota M, Kusano H, Ayabe H, Tomita M, Kamihira S. Immunohistochemical expression of sialyl Lex antigen in relation to survival of patients with colorectal carcinoma. Cancer 1993, 72:2323-2330. 10.1002/1097-0142(19931015)72:8<2323::AID-CNCR2820720807>3.0.CO;2-C, 8104679.
8. Grabowski P, Mann B, Mansmann U, Lövin N, Foss HD, Berger G, Scherübl H, Riecken EO, Buhr HJ, Hanski C. Expression of sialyl-Le(x) antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer 2000, 88:281-286. 10.1002/1097-0215(20001015)88:2<281::AID-IJC21>3.0.CO;2-2, 11004681.
9. Sperandio M. Selectins and glycosyltransferases in leukocyte rolling in vivo. FEBS J 2006, 273:4377-4389. 10.1111/j.1742-4658.2006.05437.x, 16956372.
10. Zimmerman BJ, Paulson JC, Arrhenius TS, Gaeta FCA, Granger DN. Thrombin receptor peptide-mediated leukocyte rolling in rat mesenteric venules: roles of P-selectin and sialyl Lewis X. Am J Physiol 1994, 267:H1049-H1053.
11. Byrd JC, Bresalier RS. Mucins and mucin-binding proteins in colorectal cancer. Cancer Metastasis Rev 2004, 23:77-99.
12. AWMF Accessed 25 March 2009, http://www.awmf-online.de
13. Dripps AD, Lamont A, Eckenhoff JE. The role of anesthesia in surgical mortality. JAMA. 1961, 178:261-266. 10.1001/jama.1961.03040420001001, 13887881.
14. Klautke G, Feyerherd F, Ludwig K, Prall F, Foitzik T, Fietkau R. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 2005, 92:1215-1220. 10.1038/sj.bjc.6602492, 2361958, 15785742.
15. TNM Classification of Malignant Tumors 1997, J. Wiley & Sons, New York, 5.
16. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data 1997, Springer, New York.
17. Therneau TM, Grambsch PM, Flemenig TR. Martingale-based residuals for survival models. Biometrika 1990, 77:147-160.
18. St Hill CA, Baharo-Hassan D, Farooqui M. C2-O-sLeX glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells. PLoS One 2011, 6:e16281. 10.1371/journal.pone.0016281, 3023807, 21283832.
19. Matsushita Y, Yamamoto N, Shirahama H, Tanaka S, Yonezawa S, Yamori T, Irimura T, Sato E. Expression of sulfomucins in normal mucosae, colorectal adenocarcinomas, and metastases. Jpn J Cancer Res 1995, 86:1060-1067. 10.1111/j.1349-7006.1995.tb03021.x, 8567397.
20. Fleming TR, Harrington DP. Counting Processes and Survival Analysis 2005, 448. Wiley-Interscience, Indianapolis.
21. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318. 10.1097/00000658-199909000-00004, 1420876, 10493478.
22. Lee WS, Kim MJ, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Kim YI. Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis. Langenbecks Arch Sur 2008, 393:13-19.